887 Great Northern Way, Suite 138
Member Sector: Biopharmaceuticals
Qu Biologics is at the forefront of a paradigm shift in the way we treat cancer and other immune-related disease. Rather than blocking or stimulating a single specific receptor or pathway, the company’s Site Specific Immunomodulators (SSIs), a novel class of immunotherapies, aim to restore the body’s normal immune response. SSIs, which are derived from components of inactivated common bacteria, are designed to activate the body’s innate immune response and restore normal immune function in the targeted organ or tissue to reverse the chronic inflammation underlying many chronic diseases including cancer, inflammatory bowel disease and other immune-related conditions. The company is currently recruiting participants for a clinical trial in Crohn’s disease and a Phase 2a open-label clinical trial in recurrent non-small cell lung cancer to study SSI treatment. A clinical trial in ulcerative colitis has received Health Canada approval and will begin in Q2 2015. Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com and www.qucrohnstrial.com.